GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (NAS:XOMA) » Definitions » Shiller PE Ratio

XOMA (XOMA) Shiller PE Ratio : (As of Apr. 29, 2024)


View and export this data going back to 1986. Start your Free Trial

What is XOMA Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


XOMA Shiller PE Ratio Historical Data

The historical data trend for XOMA's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Shiller PE Ratio Chart

XOMA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

XOMA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of XOMA's Shiller PE Ratio

For the Biotechnology subindustry, XOMA's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where XOMA's Shiller PE Ratio falls into.



XOMA Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

XOMA's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, XOMA's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.87/129.4194*129.4194
=-1.870

Current CPI (Dec. 2023) = 129.4194.

XOMA Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -4.200 99.695 -5.452
201406 -3.400 100.560 -4.376
201409 -3.400 100.428 -4.382
201412 -2.490 99.070 -3.253
201503 -3.800 99.621 -4.937
201506 -4.000 100.684 -5.142
201509 -0.080 100.392 -0.103
201512 4.330 99.792 5.616
201603 -1.400 100.470 -1.803
201606 -2.520 101.688 -3.207
201609 -2.080 101.861 -2.643
201612 -2.890 101.863 -3.672
201703 -2.370 102.862 -2.982
201706 0.020 103.349 0.025
201709 1.980 104.136 2.461
201712 -0.160 104.011 -0.199
201803 -0.460 105.290 -0.565
201806 -0.230 106.317 -0.280
201809 -0.550 106.507 -0.668
201812 -0.350 105.998 -0.427
201903 0.210 107.251 0.253
201906 -0.470 108.070 -0.563
201909 0.200 108.329 0.239
201912 -0.490 108.420 -0.585
202003 -0.490 108.902 -0.582
202006 -0.330 108.767 -0.393
202009 -0.100 109.815 -0.118
202012 1.320 109.897 1.554
202103 -0.700 111.754 -0.811
202106 -0.310 114.631 -0.350
202109 -0.510 115.734 -0.570
202112 1.670 117.630 1.837
202203 -0.320 121.301 -0.341
202206 -0.530 125.017 -0.549
202209 -0.480 125.227 -0.496
202212 -0.640 125.222 -0.661
202303 -0.980 127.348 -0.996
202306 -0.590 128.729 -0.593
202309 -0.600 129.860 -0.598
202312 -1.870 129.419 -1.870

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


XOMA  (NAS:XOMA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


XOMA Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of XOMA's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA (XOMA) Business Description

Traded in Other Exchanges
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Executives
Bradley Sitko officer: Chief Investment Officer C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Owen Hughes director, officer: Interim CEO C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Thomas M. Burns officer: Chief Financial Officer 2910 SEVENTH STREET, BERKELEY CA 94710
James R Neal officer: VP Business Development 2910 SEVENTH STREET, BERKELEY CA 94710
Heather L Franklin director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVE E, SEATTLE WA 98102
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Bvf Ii Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Van Ness W Denman director C/O XOMA LTD, 2910 SEVENTH ST., BERKELEY CA 94710
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Deepshikha Datta officer: Chief Business Officer 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
John Varian director, officer: Director and CEO ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Matthew D Perry director, other: See Explanation of Responses ONE SANSOME STREET, 30TH FLOOR, SAN FRANCISCO CA 94104